Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets in Hemodialysis
NCT00267514Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2006
- Primary completion
- Mar 2007
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sevelamer carbonate in hyperphosphatemia (2 arms), sponsored by Sanofi. Primary endpoints: Serum Phosphorus Levels up to 13 weeks and Safety and Tolerability up to 13 weeks. Started Jan 2006; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00267514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00267514.